CDK4/6抑制剂所致药物不良反应文献分析及思考

doi:10.3969/j.issn.2095-1264.2023.04.14

首页 > 过刊浏览>2023年第4期 >490-497. DOI:10.3969/j.issn.2095-1264.2023.04.14

CDK4/6抑制剂所致药物不良反应文献分析及思考
DOI:
                        10.3969/j.issn.2095-1264.2023.04.14
                    
作者:
                        
                        
                    
作者单位:清华大学临床医学院/清华大学附属北京清华长庚医院，北京，102218
作者简介:唐婧，女，硕士，副主任药师，研究方向：药事管理、临床药学。
通讯作者:艾超，男，硕士，副主任药师，研究方向：医院药学。
中图分类号:R979.1
基金项目:

Literature analysis and reflection on the adverse drug reactions caused by CDK4/6 inhibitors

Author:

Affiliation:

Beijing Tsinghua Changgung Hospital/School of Clinical Medicine, Tsinghua University, Beijing, 102218, China

Fund Project:

摘要

图/表

访问统计

参考文献

相似文献

引证文献

资源附件

文章评论

摘要:

目的分析CDK4/6抑制剂在临床应用中所致不良反应（ADR）的特点，为临床安全用药提供参考。方法检索维普、中国知网、万方、Web of Science、PubMed等数据库中关于CDK4/6抑制剂致ADRs的文献并进行分析。结果 CDK4/6抑制剂致ADRs的个案报道共34例；患者平均年龄约63.5岁，ADRs多发生在用药4个月内（29例，85.29%）；CDK4/6抑制剂致ADRs主要以皮肤及其附件损害（14例，41.18%）、呼吸系统损害（6例，17.65%）、肝胆系统损害（4例，11.76%）为主；经停药和/或对症治疗后达到症状好转或治愈的有31例；3例最终死亡。结论临床使用CDK4/6抑制剂时应加强用药监测，开展多学科患者管理，而CDK4/6抑制剂的ADR发生机制尚需进一步研究。

Abstract:

Objective To analyze the characteristics of adverse reactions (ADR) caused by CDK4/6 inhibitors in clinical application, so as to provide reference for clinical safe drug use.Methods Web of Science, PubMed, VIP, CNKI and Wanfang databases were searched for ADRs induced by CDK4/6 inhibitor, and the collected literatures were further analyzed statistically.Results A total of 34 cases of ADRs caused by CDK4/6 inhibitors were reported. Patients were averagely about 63.5 years old. Most of the ADRs occurred within 4 months after getting CDK4/6 inhibitors (29 cases, 85.29%). ADRs caused by CDK4/6 inhibitors mainly included damage of skin and its adnexa (14 cases, 41.18%), respiratory system damage (6 cases, 17.65%), hepatobiliary system damage (4 cases, 11.76%). 31 cases were cured or improved after drug withdrawal and/or symptomatic support. Three patients died in the end.Conclusion When using CDK4/6 inhibitors in clinic, drug safety monitoring should be strengthened to alert the occurrence of ADRs. The mechanism of adverse reactions of CDK4/6 inhibitors needs to be further studied.